PATENT CLAIM ANALYSIS

Application Number: 16176200
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["424", "188100"]

Abstract:
The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.

Claim (Index 21):
An isolated or recombinant polynucleotide encoding the modified trimeric HIV-1 envelope gp140 protein of  claim 1 .

Metadata:
- Claim Count in Document: 45.0
- Percentile: 97.0
- Lexical Diversity: 1.5814
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15508885', '14508369', '14806727', '14806735', '14806742']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8127933726198764
- 35 USC 102 Novelty (BERT): 0.5769585039569972
- Combined Prediction Score: 0.7892098857535884
- Mean Citation Score: 473.723976
- Max Citation Score: 502.7537
- Similarity Product: 395.73422706758384

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test